The global public health response to COVID-19 is pivoting from high-income European countries to MICs predominantly in Asia and South America. Effective test, trace, and isolate systems may be particularly valuable in MICs, where social and economic circumstances do not support large and long-term lockdowns. But investing in such systems in MICs comes with a number of limitations and opportunity costs.
The sizeable economic and health consequences of COVID-19 are clear as the pandemic spreads, translating into additional burden on health systems not just now but for years to come.
Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.
Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines
The global effort to control the COVID-19 pandemic has seen an exceptional allocation of public and philanthropic funds to advance the development of diagnostics, therapeutics, and vaccines as quickly as possible. While critical, even these significant commitments represent only a “down payment” on a price tag that could eventually exceed $50 billion just to scale the production of vaccines to control this global pandemic—amounts that cannot be raised through traditional donor and philanthropic commitments.
Delivering on the Promise of “Equitable Access” to Epidemic Vaccines and Treatments: the Need for Norms, Processes, and Evidence to Guide Supply and Allocation
While there has been much interest and investment in developing epidemic vaccines and medicines to combat emerging infectious disease threats, there has been less attention to how we will manage and allocate the global supply of efficacious vaccines and treatments once we have them. The launch of the Access to COVID-19 Tools (ACT) Accelerator marks an unprecedented commitment to global collaboration to ensure rapid and equitable access to medical countermeasures for COVID-19, such as vaccines and treatments.
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
As the COVID-19 pandemic accelerates, global leaders are quickly realizing that we need a bigger, better toolbox to effectively fight the novel coronavirus.
As the UK undertakes “the biggest review of Britain's place in the world since the end of the Cold War,” our experts explore how global health could be incorporated into the integrated review.
Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation
Over the past two decades, global health innovation has delivered important new tools for use in low- and middle-income countries (LMICs) and saved many lives. Nonetheless, the current innovation ecosystem suffers from significant limitations that are likely to worsen with aid transition.
The market-driven, value-based advance commitment (MVAC) builds on the advance market commitment (AMC) mechanism previously used in global health with several important innovations and improvements. Most crucially, the MVAC is driven by MIC demand rather than donor contributions; is informed by countries’ ability to pay rather than a single, “cost-plus” price; and allows pharmaceutical companies to reap higher revenues from a more effective product. In this report, we apply our new model—the MVAC—to a target product profile (TPP), published by the World Health Organization (WHO) in 2016 and endorsed by BMGF, for a pan-TB regimen.